187 related articles for article (PubMed ID: 30527174)
1. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Ng TL; Morgan RL; Patil T; Barón AE; Smith DE; Ross Camidge D
Lung Cancer; 2018 Dec; 126():112-118. PubMed ID: 30527174
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gan GN; Weickhardt AJ; Scheier B; Doebele RC; Gaspar LE; Kavanagh BD; Camidge DR
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):892-8. PubMed ID: 24462383
[TBL] [Abstract][Full Text] [Related]
4. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Weickhardt AJ; Scheier B; Burke JM; Gan G; Lu X; Bunn PA; Aisner DL; Gaspar LE; Kavanagh BD; Doebele RC; Camidge DR
J Thorac Oncol; 2012 Dec; 7(12):1807-1814. PubMed ID: 23154552
[TBL] [Abstract][Full Text] [Related]
5. SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L; Kroeze SG; Guckenberger M
Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
7. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
8. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Bronte G; Franchina T; Alù M; Sortino G; Celesia C; Passiglia F; Savio G; Laudani A; Russo A; Picone A; Rizzo S; De Tursi M; Gambale E; Bazan V; Natoli C; Blasi L; Adamo V; Russo A
Oncotarget; 2016 Jun; 7(24):35803-35812. PubMed ID: 26993607
[TBL] [Abstract][Full Text] [Related]
9. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
11. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
[TBL] [Abstract][Full Text] [Related]
13. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
[TBL] [Abstract][Full Text] [Related]
14. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
16. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
Auliac JB; Fournier C; Audigier Valette C; Perol M; Bizieux A; Vinas F; Decroisette Phan van Ho C; Bota Ouchlif S; Corre R; Le Garff G; Fournel P; Baize N; Lamy R; Vergnenegre A; Arpin D; Marin B; Chouaid C; Gervais R
Target Oncol; 2016 Apr; 11(2):167-74. PubMed ID: 26315967
[TBL] [Abstract][Full Text] [Related]
17. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
18. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.
Borghetti P; Bonù ML; Giubbolini R; Levra NG; Mazzola R; Perna M; Visani L; Meacci F; Taraborrelli M; Triggiani L; Franceschini D; Greco C; Bruni A; Magrini SM; Scotti V
Radiol Med; 2019 Jul; 124(7):662-670. PubMed ID: 30771218
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Schonewolf CA; Verma V; Post CM; Berman AT; Frick MA; Vachani A; Lin C; Simone CB
Lung Cancer; 2018 Mar; 117():53-59. PubMed ID: 28800837
[TBL] [Abstract][Full Text] [Related]
20. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]